{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:44:06Z","timestamp":1778838246803,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s13760-023-02261-7","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T03:55:04Z","timestamp":1680839704000},"page":"1447-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["C5a complement levels in clinical remission AQP4-IgG-positive NMO patients"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7940-0052","authenticated-orcid":false,"given":"Analisa","family":"Manin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano E.","family":"Justo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-216X","authenticated-orcid":false,"given":"Mariela L.","family":"Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-1482","authenticated-orcid":false,"given":"Andr\u00e9s M.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"issue":"1","key":"2261_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Primers 6(1):85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9","journal-title":"Nat Rev Dis Primers"},{"key":"2261_CR2","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, Bhojak M, Jacob A (2017) What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 264:2088\u20132094. https:\/\/doi.org\/10.1007\/s00415-017-8596-7","journal-title":"J Neurol"},{"issue":"5","key":"2261_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gilden D, Nessler S, Stadelmann C, Hemmer B (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66(5):617\u2013629. https:\/\/doi.org\/10.1002\/ana.21802","journal-title":"Ann Neurol"},{"issue":"5","key":"2261_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66(5):630\u2013643. https:\/\/doi.org\/10.1002\/ana.21837","journal-title":"Ann Neurol"},{"issue":"1","key":"2261_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 24(1):83\u201397. https:\/\/doi.org\/10.1111\/bpa.12099","journal-title":"Brain Pathol"},{"issue":"5","key":"2261_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ana.24630","volume":"79","author":"M Herwerth","year":"2016","unstructured":"Herwerth M, Kalluri SR, Srivastava R, Kleele T, Kenet S, Illes Z, Merkler D, Bennett JL, Misgeld T, Hemmer B (2016) In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol 79(5):794\u2013805. https:\/\/doi.org\/10.1002\/ana.24630","journal-title":"Ann Neurol"},{"issue":"pt 2","key":"2261_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/ana.24630","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA et al (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133(pt 2):349\u2013361. https:\/\/doi.org\/10.1002\/ana.24630","journal-title":"Brain"},{"issue":"7","key":"2261_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/nejmoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614\u2013625. https:\/\/doi.org\/10.1056\/nejmoa1900866","journal-title":"N Engl J Med"},{"issue":"6","key":"2261_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ana.26226","volume":"90","author":"CW Keller","year":"2021","unstructured":"Keller CW, Lopez JA, Wendel EM, Ramanathan S, Gross CC, Klotz L, Reindl M, Dale RC, Wiendl H, Rost\u00e1sy K, Brilot F, L\u00fcnemann JD (2021) Complement activation is a prominent feature of MOGAD. Ann Neurol 90(6):976\u2013982. https:\/\/doi.org\/10.1002\/ana.26226","journal-title":"Ann Neurol"},{"issue":"1-2","key":"2261_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","volume":"254","author":"H Kuroda","year":"2013","unstructured":"Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, Misu T, Nakashima I, Sato S, Itoyama Y, Aoki M (2013) Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254(1\u20132):178\u2013182. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.09.002","journal-title":"J Neuroimmunol"},{"key":"2261_CR11","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/1352458516669002","volume":"23","author":"S Hakobyan","year":"2017","unstructured":"Hakobyan S, Luppe S, Evans DR, Harding K, Loveless S, Robertson NP, Morgan BP (2017) Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler 23:946\u2013955. https:\/\/doi.org\/10.1177\/1352458516669002","journal-title":"Mult Scler"},{"key":"2261_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"3","key":"2261_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","volume":"23","author":"A Weinstein","year":"2021","unstructured":"Weinstein A, Alexander RV, Zack DJ (2021) A review of complement activation in SLE. Curr Rheumatol Rep 23(3):16. https:\/\/doi.org\/10.1007\/s11926-021-00984-1","journal-title":"Curr Rheumatol Rep"},{"key":"2261_CR14","doi-asserted-by":"publisher","first-page":"577699","DOI":"10.1016\/j.jneuroim.2021.577699","volume":"360","author":"F Pache","year":"2021","unstructured":"Pache F, Ringelstein M, Aktas O, Kleiter I, Jarius S, Siebert N, Bellmann-Strobl J, Paul F, Ruprecht K (2021) C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. J Neuroimmunol 360:577699. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577699","journal-title":"J Neuroimmunol"},{"key":"2261_CR15","doi-asserted-by":"publisher","first-page":"853891","DOI":"10.3389\/fimmu.2022.853891","volume":"13","author":"L Lin","year":"2022","unstructured":"Lin L, Wu Y, Hang H, Lu J, Ding Y (2022) Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD. Front Immunol 13:853891. https:\/\/doi.org\/10.3389\/fimmu.2022.853891","journal-title":"Front Immunol"},{"key":"2261_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935697","author":"F Aguirre","year":"2020","unstructured":"Aguirre F, Manin A, Fernandez VC, Justo ME, Leoni J, Paz ML, Villa AM (2020) C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286420935697","journal-title":"Ther Adv Neurol Disord"},{"issue":"15","key":"2261_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/NDT.S185336","volume":"21","author":"N Ai","year":"2019","unstructured":"Ai N, Liu H, Zhou H, Lin D, Wang J, Yang M, Song H, Sun M, Xu Q, Wei S (2019) Cytokines and chemokines expression in serum of patients with neuromyelitis optica. Neuropsychiatr Dis Treat 21(15):303\u2013310. https:\/\/doi.org\/10.2147\/NDT.S185336","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"18","key":"2261_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/NDT.S359620","volume":"17","author":"Y Tong","year":"2022","unstructured":"Tong Y, Liu J, Yang T, Wang J, Zhao T, Kang Y, Fan Y (2022) Association of pain with plasma C5a in patients with neuromyelitis optica spectrum disorders during remission. Neuropsychiatr Dis Treat 17(18):1039\u20131046. https:\/\/doi.org\/10.2147\/NDT.S359620. (PMID:35615424;PMCID:PMC9124695)","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02261-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-023-02261-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02261-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T09:36:24Z","timestamp":1689154584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-023-02261-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s13760-023-02261-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}